|Table of Contents|

Comparative study of neoadjuvant chemotherapy for cisplatin，oxaliplatin or nedaplatin in stage Ⅲ esophageal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 01
Page:
57-60
Research Field:
Publishing date:

Info

Title:
Comparative study of neoadjuvant chemotherapy for cisplatin，oxaliplatin or nedaplatin in stage Ⅲ esophageal cancer
Author(s):
WEI Changjiang; MAO Yiming; QIN Yuan; HONG Dengsen
Thoracic Surgery，Suzhou Kowloon Hospital Affiliated to Shanghai Jiaotong University School of Medicine，Jiangsu Suzhou 215000,China.
Keywords:
esophageal cancer; neoadjuvant chemotherapy; cisplatin; oxaliplatin; nedaplatin
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2021.01.012
Abstract:
Objective：To compare the efficacy and safety of neoadjuvant chemotherapy for cisplatin，oxaliplatin and nedaplatin in stage Ⅲ esophageal cancer.Methods：A prospective enrollment of 170 patients with neoadjuvant chemotherapy for stage Ⅲ esophageal cancer who met the inclusion criteria during the period from January 2014 to January 2018 in Suzhou Kowloon Hospital Affiliated to Shanghai Jiaotong University School of Medicine was performed.All patients underwent surgery to analyze their efficacy and dysfunction.The reaction occurred.The neoadjuvant chemotherapy regimen was paclitaxel plus cisplatin(n=55)，oxaliplatin(n=57) or nedaplatin(n=58)，one cycle every 3 weeks，a total of 2 cycles of neoadjuvant chemotherapy.Results：Among all patients，7 patients received CR，101 patients with PR，58 patients with SD，and 4 patients with PD.The objective effective rate was 63.5%.There was no significant difference in the overall survival between the three groups(P=0.462).Adverse reactions included myelosuppression，liver damage，renal impairment，vomiting，and diarrhea.The incidence of grade Ⅲ-Ⅳ adverse reactions was 5.9%(10/170).Comparison between groups showed that nedaplatin and oxaliplatin were as effective as cisplatin，but the incidence of creatinine and vomiting was significantly lower than that of cisplatin，and the incidence of oxaliplatin diarrhea was significantly higher than the other two groups.Conclusion：Nidaplatin and oxaliplatin are not inferior to cisplatin in neoadjuvant chemotherapy for stage Ⅲ esophageal cancer，but the adverse reaction rate is significantly reduced.

References:

[1]RUBENSTEIN JH，SHAHEEN NJ.Epidemiology，diagnosis，and management of esophageal adenocarcinoma［J］.Gastroenterology，2015，149(2)：302-317.
[2]MOORCRAFT SY，SMYTH EC，CUNNINGHAM D.Adjuvant or neoadjuvant therapy for operable esophagogastric cancer［J］.Gastric Cancer，2015，18(1)：1-10.
[3]YAMASHITA K，MINE S，TOIHATA T，et al.The usefulness of three-dimensional video-assisted thoracoscopic esophagectomy in esophageal cancer patients［J］.Esophagus，2019,16(3):272-277.
[4]HEGEMANN NS，KOEPPLE R，WALTER F，et al.Neoadjuvant chemoradiation for esophageal cancer：Surgery improves locoregional control while response based on FDG-PET/CT predicts survival［J］.Strahlenther Onkol，2018，194(5)：435-443.
[5]SHEPARD G，ARROWSMITH ER，MURPHY P，et al.A phase II study with lead-in safety cohort of 5-fluorouracil，oxaliplatin，and lapatinib in combination with radiation therapy as neoadjuvant treatment for patients with localized HER2-positive esophagogastric adenocarcinomas［J］.Oncologist，2017，22(10)：1152-1198.
[6]TANAKA Y，YOSHIDA K，TANAHASHI T，et al.Phase II trial of neoadjuvant chemotherapy with docetaxel，nedaplatin，and S1 for advanced esophageal squamous cell carcinoma［J］.Cancer Sci，2016，107(6)：764-772.
[7]SCHWEIGERT M，DUBECZ A，STEIN HJ.Oesophageal cancer-an overview［J］.Nat Rev Gastroenterol Hepatol，2013，10(4)：230-244.
[8]KUMARAN D，JOHN S，ISIAH R，et al.Management of locally advanced carcinoma oesophagus with radiation/chemoradiation：Single institute experience［J］.J Gastrointest Cancer，2016，47(3)：313-317.
[9]NOBLE F，NOLAN L，BATEMAN AC，et al.Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus［J］.World J Gastroenterol，2013，19(48)：9282-9293.
[10]鲁文君，姜雷，甘亮亮，等.新辅助化疗治疗食管癌疗效及安全性的Meta分析［J］.现代肿瘤医学，2015，23（4）：474-479. LU WJ,JIANG L,GAN LL,et al.A Meta-analysis of neoadjuvant chemotherapy and surgery alone for esophageal neoplasms［J］.Modern Oncology，2015，23（4）：474-479.
[11]PASQUALI S，YIM G，VOHRA RS，et al.Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma［J］.Ann Surg，2017，265(3)：481-491.
[12]BURMEISTER BH，THOMAS JM，BURMEISTER EA，et al.Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial［J］.Eur J Cancer，2011，47(3)：354-360.
[13]GARCIA-DEL-MURO X，MAROTO P，GUMA J，et al.Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma：A spanish germ cell cancer group study［J］.J Clin Oncol，2008，26(33)：5416-5421.
[14]STAHL M，WALZ MK，STUSCHKE M，et al.Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction［J］.J Clin Oncol，2009，27(6)：851-856.
[15]AL-BATRAN SE，HOMANN N，PAULIGK C，et al.Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer：The AIO-FLOT3 trial［J］.JAMA Oncol，2017，3(9)：1237-1244.
[16]MUKHERJEE S，HURT CN，GWYNNE S，et al.NEOSCOPE：A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma［J］.Eur J Cancer，2017，74：38-46.
[17]ZHANG F，WANG Y，WANG ZQ，et al.Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma：A systematic review and meta-analysis［J］.Dis Esophagus，2017，30(2)：1-8.
[18]强勇，杨楠，董国华，等.紫杉醇联合顺铂新辅助化疗对Ⅲ期食管癌手术风险及预后的影响［J］.临床肿瘤学杂志，2016(02)：166-169. QIANG Yong，YANG Nan，DONG Guohua，et al.Effect of paclitaxel combined with cisplatin neoadjuvant chemotherapy on the surgical risk and prognosis of stage Ⅲ esophageal cancer［J］.Journal of Clinical Oncology，2016(02)：166-169.
[19]刘丽英，岳寒.替吉奥联合奥沙利铂治疗老年晚期食管癌临床观察［J］.中国医师进修杂志，2016(4)：374-375. LIU Liying，YUE Han.Clinical observation of Tiggio combined with oxaliplatin in the treatment of elderly advanced esophageal cancer［J］.Chinese Journal of Postgraduates of Medicine，2016(4)：374-375.
[20]樊青霞，王瑞，路平，等.奈达铂联合替加氟治疗晚期食管癌［J］.中华肿瘤杂志，2008，30(12)：937-939. FAN Qingxia，WANG Rui，LU Ping，et al.Nedaplatin combined with tegafur in the treatment of advanced esophageal cancer［J］.Chin J Oncol，2008，30(12)：937-939.

Memo

Memo:
-
Last Update: 2020-11-30